EZH2 and breast carcinoma: This process translates into a decreased sensitivity of ER+ breast cancer cells to endocrine therapy, which involves an enhancer of zeste homolog 2 (EZH2)-mediated reprogramming that also seems to induce stemness in breast cancer bone metastasis (37).